Skip to content

Creative Medical Technology Holdings, Inc.: 10-Q filed 2025-08-08

What Creative Medical Technology Holdings, Inc. reported in its quarterly report filed 2025-08-08 (fiscal Q2 2025): 38 published measures, 111 facts as tagged in accession 0001477932-25-005614.

This filing

Form
10-Q (quarterly report)
Filed
2025-08-08
Fiscal period
fiscal Q2 2025
Accession
0001477932-25-005614 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Creative Medical Technology Holdings, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-06-307,105,228USD
At 2024-12-316,669,143USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-06-30277,644USD
At 2024-12-31327,644USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-06-306,827,584USD
At 2025-03-318,060,887USD
At 2024-12-316,341,499USD
At 2024-06-307,613,434USD
At 2024-03-319,228,618USD
At 2023-12-3110,343,796USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-1,233,303USD91
2025-01-01 to 2025-06-30-2,871,400USD181
2024-04-01 to 2024-06-30-1,557,728USD91
2024-01-01 to 2024-06-30-2,599,272USD182

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-06-30-2,750,282USD181
2024-01-01 to 2024-06-30-2,366,168USD182

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2025-04-01 to 2025-06-300USD91
2025-01-01 to 2025-06-303,000USD181
2024-04-01 to 2024-06-308,000USD91
2024-01-01 to 2024-06-308,000USD182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-06-303,354,000USD181
2024-01-01 to 2024-06-30-149,414USD182

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2025-01-01 to 2025-06-300USD181
2024-01-01 to 2024-06-306,520,191USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-06-30-67,463,313USD
At 2024-12-31-64,591,913USD

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-04-01 to 2025-06-302,580,532shares91
2025-01-01 to 2025-06-302,282,290shares181
2024-04-01 to 2024-06-301,405,208shares91
2024-01-01 to 2024-06-301,413,324shares182

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-0.48USD/shares91
2025-01-01 to 2025-06-30-1.26USD/shares181
2024-04-01 to 2024-06-30-1.11USD/shares91
2024-01-01 to 2024-06-30-1.84USD/shares182

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2025-04-01 to 2025-06-300USD91
2025-01-01 to 2025-06-300USD181
2024-04-01 to 2024-06-300USD91
2024-01-01 to 2024-06-300USD182

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-01-01 to 2025-06-303,485USD181
2024-04-01 to 2024-06-309,162USD91
2024-01-01 to 2024-06-3018,324USD182

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-1,263,520USD91
2025-01-01 to 2025-06-30-2,923,998USD181
2024-04-01 to 2024-06-30-1,625,306USD91
2024-01-01 to 2024-06-30-2,748,453USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-06-306,632,707USD
At 2024-12-316,135,303USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-06-30277,644USD
At 2024-12-31327,644USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2025-06-30263,450USD
At 2024-12-31273,530USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2025-06-30469,240USD
At 2024-12-31530,559USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2025-01-01 to 2025-06-3010,000USD181
2024-01-01 to 2024-06-30149,514USD182

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-04-01 to 2025-06-301,263,520USD91
2025-01-01 to 2025-06-302,925,798USD181
2024-04-01 to 2024-06-301,630,106USD91
2024-01-01 to 2024-06-302,753,253USD182

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2025-06-30994USD
At 2024-12-312,194USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2025-04-01 to 2025-06-300USD91
2025-01-01 to 2025-06-301,800USD181
2024-04-01 to 2024-06-304,800USD91
2024-01-01 to 2024-06-304,800USD182

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2025-04-01 to 2025-06-300USD91
2025-01-01 to 2025-06-301,200USD181
2024-04-01 to 2024-06-303,200USD91
2024-01-01 to 2024-06-303,200USD182

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2025-04-01 to 2025-06-30731,517USD91
2025-01-01 to 2025-06-301,619,914USD181
2024-04-01 to 2024-06-30676,086USD91
2024-01-01 to 2024-06-301,347,570USD182

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-04-01 to 2025-06-30501,261USD91
2025-01-01 to 2025-06-301,244,565USD181
2024-04-01 to 2024-06-30924,749USD91
2024-01-01 to 2024-06-301,347,141USD182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-06-302,580,532shares
At 2024-12-311,748,428shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-06-306,544,120USD
At 2024-12-315,940,402USD
At 2024-06-307,471,476USD
At 2023-12-313,466,867USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-06-3074,298,311USD
At 2024-12-3170,931,663USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2025-06-300USD
At 2024-12-3139,920USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2025-06-3087,593USD
At 2024-12-31192,707USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-1,233,303USD91
2025-01-01 to 2025-06-30-2,871,400USD181
2024-04-01 to 2024-06-30-1,557,728USD91
2024-01-01 to 2024-06-30-2,599,272USD182

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2025-01-01 to 2025-06-30-2,871,400USD181
2024-01-01 to 2024-06-30-2,599,272USD182

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2025-04-01 to 2025-06-3030,742USD91
2025-01-01 to 2025-06-3061,319USD181
2024-04-01 to 2024-06-3029,271USD91
2024-01-01 to 2024-06-3058,542USD182

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2025-04-01 to 2025-06-3030,217USD91
2025-01-01 to 2025-06-3052,598USD181
2024-04-01 to 2024-06-3067,578USD91
2024-01-01 to 2024-06-30149,181USD182

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2025-01-01 to 2025-06-300USD181
2024-01-01 to 2024-06-300USD182

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2025-01-01 to 2025-06-300USD181
2024-01-01 to 2024-06-300USD182

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-06-30-1,200USD181
2024-01-01 to 2024-06-30-3,200USD182

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-06-30-10,080USD181
2024-01-01 to 2024-06-304,878USD182

Inspect the source

Entity
Creative Medical Technology Holdings, Inc. / CIK 0001187953
Captured
2026-09-20T07:45:17.099Z
SEC response SHA-256
89e881c0f2d97477b4adfc3e19e7ae581dc54b90e3254331c852038e8d4c6961

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001187953.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))